110 related articles for article (PubMed ID: 26945272)
1. Prevalence of Occult Malignancy Within Morcellated Specimens Removed During Laparoscopic Sacrocolpopexy.
Vallabh-Patel V; Saiz C; Salamon C; Francis A; Pagnillo J; Culligan P
Female Pelvic Med Reconstr Surg; 2016; 22(4):190-3. PubMed ID: 26945272
[TBL] [Abstract][Full Text] [Related]
2. Morcellation of occult uterine malignancies: an Australian single institution retrospective study.
Tan A; Salfinger S; Tan J; Cohen P
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):503-6. PubMed ID: 26314239
[TBL] [Abstract][Full Text] [Related]
3. Safety of Manual Morcellation After Vaginal or Laparoscopic-assisted Vaginal Hysterectomy.
Balgobin S; Maldonado PA; Chin K; Schaffer JI; Hamid CA
J Minim Invasive Gynecol; 2016; 23(4):542-7. PubMed ID: 26802908
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Occult Uterine Pathology in Women Undergoing Hysterectomy With Pelvic Organ Prolapse Repair.
Ackenbom MF; Giugale LE; Wang Y; Shepherd JP
Female Pelvic Med Reconstr Surg; 2016; 22(5):332-5. PubMed ID: 27171317
[TBL] [Abstract][Full Text] [Related]
5. Incidental gynecologic neoplasms in morcellated uterine specimens: a case series with follow-up.
Ehdaivand S; Simon RA; Sung CJ; Steinhoff MM; Lawrence WD; Quddus MR
Hum Pathol; 2014 Nov; 45(11):2311-7. PubMed ID: 25257577
[TBL] [Abstract][Full Text] [Related]
6. Incidental power morcellation of malignancy: a retrospective cohort study.
Graebe K; Garcia-Soto A; Aziz M; Valarezo V; Heller PB; Tchabo N; Tobias DH; Salamon C; Ramieri J; Dise C; Slomovitz BM
Gynecol Oncol; 2015 Feb; 136(2):274-7. PubMed ID: 25740603
[TBL] [Abstract][Full Text] [Related]
7. Occult Uterine Malignancy at the Time of Surgery for Pelvic Organ Prolapse: A Systematic Review and Meta-analysis.
Davenport E; James L; Parks T; Howard DL
Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):e282-e289. PubMed ID: 32604198
[TBL] [Abstract][Full Text] [Related]
8. Risk of Undetected Cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB; Handal-Orefice R; Hanchate AD; Lin M; Paasche-Orlow MK
Womens Health Issues; 2016; 26(1):21-6. PubMed ID: 26701205
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy With Morcellation.
Wasson M; Magtibay P; Magtibay P; Magrina J
J Minim Invasive Gynecol; 2017; 24(4):665-669. PubMed ID: 28254678
[TBL] [Abstract][Full Text] [Related]
10. The incidence of occult malignancy following uterine morcellation: A ten-year single institution experience retrospective cohort study.
Mori KM; Abaid LN; Mendivil AA; Brown JV; Beck TL; Micha JP; Epstein HD; Goldstein BH
Int J Surg; 2018 May; 53():239-242. PubMed ID: 29621658
[TBL] [Abstract][Full Text] [Related]
11. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T; Tucker LY; Zaritsky E; Littell RD; Palen T; Neugebauer R; Axtell A; Schultze PM; Kronbach DW; Embry-Schubert J; Sundang A; Bischoff K; Compton-Phillips AL; Lentz SE
Obstet Gynecol; 2016 Jan; 127(1):29-39. PubMed ID: 26646120
[TBL] [Abstract][Full Text] [Related]
12. Unanticipated uterine pathologic finding after morcellation during robotic-assisted supracervical hysterectomy and cervicosacropexy for uterine prolapse.
Hill AJ; Carroll AW; Matthews CA
Female Pelvic Med Reconstr Surg; 2014; 20(2):113-5. PubMed ID: 24566217
[TBL] [Abstract][Full Text] [Related]
13. Complication rate of uterine morcellation in laparoscopic supracervical hysterectomy: a retrospective cohort study.
Smits RM; De Kruif JH; Van Heteren CF
Eur J Obstet Gynecol Reprod Biol; 2016 Apr; 199():179-82. PubMed ID: 26943477
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of occult pre-malignant or malignant pathology at the time of uterine morcellation for benign disease.
Von Bargen EC; Grimes CL; Mishra K; Wang R; Haviland MJ; Hacker MR; Carnevale JA; Estes AJ; Elkadry EA
Int J Gynaecol Obstet; 2017 May; 137(2):123-128. PubMed ID: 28170091
[TBL] [Abstract][Full Text] [Related]
15. Occult Uterine Malignancy at the Time of Sacrocolpopexy in the Context of the Safety Communication on Power Morcellation by the FDA.
Chang OH; Ferrando CA
J Minim Invasive Gynecol; 2021 Apr; 28(4):788-793. PubMed ID: 32681994
[TBL] [Abstract][Full Text] [Related]
16. Occult uterine malignancy during laparoscopic supracervical hysterectomy.
Gawron I; Skotniczny K; Ludwin A
Ginekol Pol; 2018; 89(9):467-474. PubMed ID: 30318572
[TBL] [Abstract][Full Text] [Related]
17. Risk of occult malignancy in morcellated hysterectomy: a case series.
Hagemann IS; Hagemann AR; LiVolsi VA; Montone KT; Chu CS
Int J Gynecol Pathol; 2011 Sep; 30(5):476-83. PubMed ID: 21804400
[TBL] [Abstract][Full Text] [Related]
18. Morcellation and the Incidence of Occult Uterine Malignancy: A Dual-Institution Review.
Picerno TM; Wasson MN; Gonzalez Rios AR; Zuber MJ; Taylor NP; Hoffman MK; Borowsky ME
Int J Gynecol Cancer; 2016 Jan; 26(1):149-55. PubMed ID: 26332395
[TBL] [Abstract][Full Text] [Related]
19. Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids.
Cui RR; Wright JD
Clin Obstet Gynecol; 2016 Mar; 59(1):103-18. PubMed ID: 26645385
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications.
Parsons LHP; Pedersen R; Richardson DL; Kho KA
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():108-112. PubMed ID: 29518640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
